# Only 10% of overweight or obese individuals are using GLP-1 injectable and oral medications.

*biotech · news · 2026-04-17 · Devdiscourse*

## Key points

- Eli Lilly estimates only about 50% of eligible patients may access weight-loss drugs long term.
- Currently, just 10% of overweight or obese people use GLP-1 medications.
- Statin usage rates are viewed as a likely ceiling for future weight-loss drug adoption.
- Lilly's new oral drug Foundayo faces production scaling and high price barriers to broader adoption.

**Companies:** Eli Lilly, Novo Nordisk

[Read the full story on Devdiscourse](https://www.devdiscourse.com/article/technology/3878033-the-future-of-weight-loss-drugs-challenges-and-market-potential)

---

Canonical: https://newsio.io/n/8890ff62-6cd1-474c-acfc-5631e8ea7cda/only-10-of-overweight-or-obese-individuals-are-using-glp-1-injectable-and-oral-m
Summarized by Newsio from Devdiscourse. https://newsio.io/how-it-works